Recombinant porcine sequence factor <scp>VIII</scp> (rp<scp>FVIII</scp>) for acquired haemophilia A: practical clinical experience of its use in seven patients

Abstract

rpFVIII showed good haemostatic efficacy with no recurrences in most cases, with consumption substantially less than in the registration study. Treatment decisions were based on FVIII activity levels and clinical assessment. The ability to titrate rpFVIII dose using FVIII activity was considered advantageous compared with BPA therapy. Notable delays in diagnosis were observed.